Zydus announced on Wednesday that it has received permission from CDSCO, India, to initiate the Phase II clinical study of NLRP3 inhibitor “ZYIL1” in patients with Amyotrophic Lateral Sclerosis (ALS). “Zydus has always aimed at improving the quality of life of patients through its life-changing discoveries. This study is a positive step in this direction …
